Journal
AMERICAN HEART JOURNAL
Volume 168, Issue 1, Pages 23-29Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2014.03.021
Keywords
-
Categories
Funding
- Bayer
- National Institute for Health Research [NF-SI-0510-10140] Funding Source: researchfish
Ask authors/readers for more resources
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an a-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available